Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ACELYRIN, INC. - Common Stock (NQ: SLRN )

2.165 -0.035 (-1.59%)
Streaming Delayed Price Updated: 2:33 PM EST, Jan 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,206,525
Open 2.180
Bid (Size) 2.160 (188)
Ask (Size) 2.170 (18)
Prev. Close 2.200
Today's Range 2.000 - 2.350
52wk Range 1.910 - 8.885
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nasdaq Down 1.5%; RPM Posts Upbeat Results
Via Benzinga
Dow Surges Over 100 Points; US Trade Deficit Widens In November
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
-34.39%
-34.39%
1 Month
-49.53%
-49.53%
3 Month
-54.03%
-54.03%
6 Month
-57.55%
-57.55%
1 Year
-71.29%
-71.29%

More News

Read More
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Earnings Scheduled For November 13, 2024
Via Benzinga
Earnings Preview: Acelyrin
Via Benzinga
SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024
Via InvestorPlace
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease
From ACELYRIN, INC.
Via GlobeNewswire
What's Going On With ACELYRIN Shares Friday?
Via Benzinga
Rivian Automotive, Cerence, Nu Skin Enterprises And Other Big Stocks Moving Higher On Friday
Via Benzinga
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
From ACELYRIN, INC.
Via GlobeNewswire
Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
From ACELYRIN, INC.
Via GlobeNewswire
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep
Via Benzinga
Ouster Reports Weak Sales, Joins Brinker International And Other Big Stocks Moving Lower In Wednesday Pre-Market Session
Via Benzinga
ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
From ACELYRIN, INC.
Via GlobeNewswire
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.